Search
Menu
Home
HTB
2022
February
February 2022
Contents
Editorial
HTB: no. 1/2 (January/February 2022)
i-Base appeal: please support i-Base with £5 or £10 a month
Conference reports
CROI 2022 to only be virtual: programme online
Antiretrovirals
US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine
Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent
Guidelines
BHIVA interim guidance on long-acting cabotegravir and rilpivirine injections
Coinfections and complications
HIV-associated reductions in telomere length are stopped by effective ART
Drug resistance
Drug resistance profile of integrase inhibitors when treating HIV-2
Other news
EACS HIV Summer School 2022: Applications are open
COVID-19: investigational drugs
UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19
COVID-19: guidelines
IDSA update COVID-19 guidelines (January 2022)
Job vacancies
i-Base vacancy: HIV treatment advocate and information officer
PDFs
HTB: no. 1/2 – plus HIV and COVID-19 (7 February 2022)
HTB RSS
Early access
HIV organisations support trans and non-binary communities against the unworkable EHRC guidelines
30 June 2025
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
28 June 2025
Clinical studies of two once-weekly pipeline compounds put on hold
27 June 2025
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
All early access reports
Current issues
June 2025
May 2025
April 2025
Back issues
Special report
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate